Výsledky vyhledávání - "cardiorenal syndrome (CRS)"

Akademický článek

Risk factors and early prediction of cardiorenal syndrome type 3 among acute kidney injury patients: a cohort study.

Autor: Lin, Hui¹ (AUTHOR), Guo, Xiaoyu² (AUTHOR), Wang, Mengzhu¹ (AUTHOR), Su, Xiaole¹ (AUTHOR), Qiao, Xi¹ (AUTHOR) qiaoxi7347@vip.163.com

Publikováno v: Renal Failure. Dec2024, Vol. 46 Issue 2, p1-10. 10p.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Risk factors and early prediction of cardiorenal syndrome type 3 among acute kidney injury patients: a cohort study

Autor: Hui Lin, Xiaoyu Guo, Mengzhu Wang, Xiaole Su, Xi Qiao

Publikováno v: Renal Failure, Vol 46, Iss 1 (2024)

Background Type 3 cardiorenal syndrome (CRS type 3) triggers acute cardiac injury from acute kidney injury (AKI), raising mortality in AKI patients. We aimed to identify risk factors for CRS type 3 and develop a predictive nomogram.Methods In this re

Externí odkaz: https://doaj.org/article/148b6d1a5322431396f935ff75c43809

Zobrazit plný text záznamu

Sacubitril-Valsartan Improves Anemia of Cardiorenal Syndrome (CRS)

Autor: Rosa Diaz Campillejo, Guillermo Gervasini, J. Villa, Nicolás Roberto Robles, Elena Garcia de Vinuesa, Julian Valladares

Publikováno v: Cardiovascular & Hematological Agents in Medicinal Chemistry. 19:93-97

Background and Aims: Anemia is a common complication of heart failure and Chronic Kidney Disease (CKD). Sacubitril-valsartan is a novel therapy for the treatment of chronic Heart Failure with a reduced Ejection Fraction (HFrEF). We have evaluated the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ea31502d2e6b9bf46219a63a9b7e672
https://doi.org/10.2174/1871525718666200506095537

Zobrazit plný text záznamu

Dissertation/ Thesis

Cardiorenal syndrome (CRS): type 4 CRS

Autor: Ana Luísa Pinheiro da Silva

Externí odkaz: https://repositorio-aberto.up.pt/handle/10216/88363

Zobrazit plný text záznamu

Editorial & Opinion

ASK-1, a new target in treating cardiorenal syndrome (CRS).

Autor: Zhong P; Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Cardiovascular Research Institute of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Cardiology, Wuhan 430060, China., Yuan M; Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Cardiovascular Research Institute of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Cardiology, Wuhan 430060, China., Kong B; Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Cardiovascular Research Institute of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Cardiology, Wuhan 430060, China., Huang H; Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Cardiovascular Research Institute of Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Cardiology, Wuhan 430060, China. Electronic address: Huanghe1977@whu.edu.cn.

Publikováno v: International journal of cardiology [Int J Cardiol] 2020 Oct 01; Vol. 316, pp. 208.

Zobrazit plný text záznamu

Editorial & Opinion

RE: ASK1, a new target in treating cardiorenal syndrome (CRS).

Autor: Savira F; Biomarker Discovery Laboratory, Baker Heart and Diabetes Research Institute, Melbourne, Australia; Monash Centre of Cardiovascular Research and Education in Therapeutics, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia., Kompa AR; Monash Centre of Cardiovascular Research and Education in Therapeutics, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia; Department of Medicine, University of Melbourne, St Vincent's Hospital, Fitzroy, Australia., Edgley AJ; Department of Medicine, University of Melbourne, St Vincent's Hospital, Fitzroy, Australia., Jucker BM; Heart Failure Discovery Performance Unit, GlaxoSmithKline, King of Prussia, PA, USA., Willette RN; Heart Failure Discovery Performance Unit, GlaxoSmithKline, King of Prussia, PA, USA., Kelly DJ; Department of Medicine, University of Melbourne, St Vincent's Hospital, Fitzroy, Australia., Wang BH; Biomarker Discovery Laboratory, Baker Heart and Diabetes Research Institute, Melbourne, Australia; Monash Centre of Cardiovascular Research and Education in Therapeutics, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia. Electronic address: bing.wang@baker.edu.au.

Publikováno v: International journal of cardiology [Int J Cardiol] 2020 Oct 01; Vol. 316, pp. 207.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání